1 research outputs found
Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase IIα) in borderline ovarian tumors: Correlation with clinicopathological features
Background. The expression of p53 has been
studied not only in primary human ovarian carcinomas,
but also in borderline ovarian tumors, however, the
results were discordant. Expression patterns of proteins
involved in cell proliferation and apoptosis have been
investigated in various human neoplasms, including
female genital tract neoplasms.
Objective. The aim of this investigation was to
assess the staining pattern and immunolocalization of
p53 and selected proliferative markers (Ki-67, MCM3,
PCNA, and topoisomerase IIα) in borderline ovarian
tumors (BOTs).
Design. The study group consisted of 42 women
who underwent pelvic surgery between 2006-2015. The
median patients’ age was 46 years. The immunoperoxidase technique was employed using antibodies
against p53, Ki-67, MCM3, PCNA, and topoisomerase
IIα.
Results. For p53, nuclear expression was observed in
BOTs, however, cytoplasmatic immunoreactivity was
also detected. Altogether, 25 (60%) tumors demonstrated
positive p53 immunostaining, including overexpression
found in 6 (14%). There were no significant differences
in p53 expression between subgroups of clinicopathological variables. Immunoexpression of Ki-67,
MCM3, PCNA, and topoisomerase IIα was nuclear. Ki67 expression was positive in 12 (29%) cases and there
was a trend towards a relationship between patients’ age
and Ki-67 staining (P=0.08). Interestingly, a
significantly higher Ki-67 expression was found in
tumors of ≥10 cm in diameter compared to smaller
tumors (P=0.008). MCM3 expression was detected in 38
(90%) tumors, and PCNA expression in 28 (67%), yet
none of clinico-pathological factors was related to them.
Topoisomerase IIα expression was present in 14 (33%)
cases and, interestingly, its significantly higher
expression was observed in BOTs of ≥10 cm in diameter
compared to smaller tumors (P=0.008). Moreover,
Spearman’s correlation revealed highly significant
positive associations between Ki-67 and topoisomerase
IIα (R=0.403, P=0.008) and Ki-67 and MCM3
(R=0.469, P=0.001).
Conclusions. We report a high positive
immunostaining rate for p53, suggesting a role of TP53
alterations in the development of BOTs in humans. The
new finding of higher topoisomerase IIα immunostaining positivity in BOTs of ≥10 cm may be clinically
relevant and requires further studies on larger patient
groups